PARADIGM is the first prospective clinical study to test the superiority of Panitumumab over Bevacizumab, in combination with the standard chemo modified FOLFOX-6 treatment in patients with RAS wild-type metastatic colorectal cancer. The findings in the primary endpoint is that the overall survival in the left-sided population, if positive result, we move the whole world to test overall survival in the overall population, to define both the left-sided and the right-sided population, hierarchical way...
PARADIGM is the first prospective clinical study to test the superiority of Panitumumab over Bevacizumab, in combination with the standard chemo modified FOLFOX-6 treatment in patients with RAS wild-type metastatic colorectal cancer. The findings in the primary endpoint is that the overall survival in the left-sided population, if positive result, we move the whole world to test overall survival in the overall population, to define both the left-sided and the right-sided population, hierarchical way.
So, results show we got the survival benefit primary endpoint met in the left-sided population as well as the right-sided population, with hazard ratio around 0.80, so favoring the Panitumumab over Bevacizumab. So, second endpoints showing the standard response rate and R0 curative resection rate is very high in Panitumumab over Bevacizumab.
So, in conclusion, my presentation is that a new standard care of the Panitumumab modified FOLFOX-6 treatment, over Bevacizumab modified FOLFOX-6, in patients with RAS wild-type left-sided tumor population.